Previous close | 0.2500 |
Open | 0.3000 |
Bid | 0.1500 |
Ask | 0.2500 |
Strike | 2.50 |
Expiry date | 2024-10-18 |
Day's range | 0.2000 - 0.3100 |
Contract range | N/A |
Volume | |
Open interest | 3.63k |
New analysis of the pivotal Phase 3 SOLOIST-WHF trial demonstrates INPEFA cost-effectiveness Findings consistent with another study recently published in the Journal of Comparative Effectiveness Research THE WOODLANDS, Texas, June 18, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the peer-reviewed Journal of the American College of Cardiology: Heart Failure has published a research paper concluding that INPEFA® (sotagliflozin) is cost-effective for pe
THE WOODLANDS, Texas, June 14, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that three poster presentations will be delivered during the 84th Scientific Sessions of the American Diabetes Association being held June 21 - 24, 2024 at the Orange County Convention Center in Orlando, Florida. All three poster presentations will occur on Sunday, June 23, 12:30 - 1:30 p.m. ET, in the Poster Hall (West A-4-B2). Details are as follows: "Patient-Reported Burden of
Tango Therapeutics (TNGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.